Multiple sclerosis

New England Journal of Medicine

Volumn 343, Issue 13, 2000, Pages 938-952

  Noseworthy, John H ^a   Lucchinetti, Claudia ^a   Rodriguez, Moses ^a   Weinshenker, Brian G ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; CORTICOSTEROID; GLATIRAMER; IMMUNOGLOBULIN; INTERFERON BETA SERINE; MITOXANTRONE;

CLINICAL TRIAL; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; HEREDITY; HUMAN; HUMAN CELL; HUMAN TISSUE; META ANALYSIS; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE; PATHOGENESIS; PLASMAPHERESIS; PRIORITY JOURNAL; REVIEW;

DISEASE PROGRESSION; GLUCOCORTICOIDS; HUMANS; INTERFERON-BETA; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS; PLASMA EXCHANGE; RECURRENCE;

EID: 0034727066     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200009283431307     Document Type: Review

References (104)

1. Progress in determining the causes and treatment of multiple sclerosis
2. Revised estimate of the prevalence of multiple sclerosis in the United States
3. The natural history of multiple sclerosis: A geographically based study I. Clinical course and disability
4. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols
5. The role of magnetic resonance techniques in understanding and managing multiple sclerosis
6. Practice parameter: The usefulness of evoked potentials in identifying clinically silent lesions in patients with suspected multiple sclerosis (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology
7. The prognostic value of brain MRin clinically isolated syndromes of the CNS: A 10-year follow-up
8. The predictive value of CSF oligoclonal banding for MS 5 years after optic neuritis
9. The natural history of multiple sclerosis: A geographically based study 4. Applications to planning and interpretation of clinical therapeutic trials
10. The natural history of multiple sclerosis: A geographically based study 6. Applications to planning and interpretation of clinical therapeutic trials in primary progressive multiple sclerosis
11. Cause of death in patients attending multiple sclerosis clinics
12. Epidemiology of multiple sclerosis
13. Multiple sclerosis: Changing times
14. Epidemiology of multiple sclerosis in northwestern Sardinia: Further evidence for higher frequency in Sardinians compared to other Italians
15. Prevalence of multiple sclerosis in the region of Osona, Catalonia, northern Spain
16. A reappraisal of the epidemiology of multiple sclerosis in Olmsted County, Minnesota
17. Incidence of MS during two fifteen-year periods in the Gothenburg region of Sweden
18. Declining incidence of multiple sclerosis in the Orkney Islands
19. Epidemiologic trends in multiple sclerosis in More and Romsdal, Norway: A prevalence/incidence study in a stable population
20. Multiple sclerosis in the Faroe Islands. III. An alternative assessment of the three epidemics
21. Risk of multiple sclerosis related to age at immigration to Israel
22. Annual incidence, prevalence, and mortality of multiple sclerosis in white South-African-born and in white immigrants to South Africa
23. Multiple sclerosis among United Kingdom-born children of immigrants from the Indian subcontinent, Africa and the West Indies
24. Risk factors for multiple sclerosis: Race or place?
25. A genetic basis for familial aggregation in multiple sclerosis
26. A population-based study of multiple sclerosis in twins: Update
27. Multiple sclerosis: Updated risks for relatives
28. Histocompatibility determinants in multiple sclerosis, with special reference to clinical course
29. DRB1-DQA1-DQB1 loci and multiple sclerosis predisposition in the Sardinian population
30. A genome screen in multiple sclerosis reveals susceptibility loci on chromosome 6p21 and 17q22
31. A full genome search in multiple sclerosis
32. A complete genomic screen for multiple sclerosis underscores a role for the major histocompatability complex
33. Genomewide scan of multiple sclerosis in Finnish multiplex families
34. Linkage of the MHC to familial multiple sderosis suggests genetic heterogeneity
35. The genetics of multiple sclerosis: Principles, background and updated results of the United Kingdom systematic genome screen
36. Genomic sharing surrounding alleles identical by descent: Effects of genetic drifr and population growth
37. Prognosis in multiple sclerosis: Genetic factors
38. Major histocompatibility complex class II alleles and the course and outcome of MS: A population-based study
39. Association of interleukin-1beta and interleukin-1 receptor antagonist genes with disease severity in MS
40. Immunoglobulin G Fc-receptor (Fc γ R) IIA and IIIB polymorphisms related to disability in MS
41. Association of the APOE epsilon4 allele with disease activity in multiple sclerosis
42. Biotechnological agents for the immunotherapy of multiple sclerosis: Principles, problems and perspectives
43. Immunopathology of multiple sclerosis: Report on an international meeting held at the Institute of Neurology of the University of Vienna
44. Chronic stage multiple sclerosis lesions contain a relatively quiescent population of oligodendrocyte precursor cells
45. Demyelinating diseases - New pathological insights, new therapeutic targets
46. Absence of neurological deficits following extensive demyelination in a class I-deficient murine model of multiple sclerosis
47. Axonal transection in the lesions of multiple sclerosis
48. A quantitative analysis of oligodendrocytes in multiple sclerosis lesions: A study of 113 cases
49. Acute axonal injury in multiple sclerosis: Correlation with demyelination and inflammation
50. Multiple sclerosis: Comparison of the human T-cell response to S100β and myelin basic protein reveals parallels to rat experimental autoimmune panencephalitis
51. The small heat-shock protein αB-crystallin as candidate autoantigen in multiple sclerosis
52. Multiple sclerosis: A coordinated immunological attack against myelin in the central nervous system
53. Multiple sclerosis: Lessons from neuropathology
54. The demyelinating potential of antibodies to myelin oligodendrocyte glycoprotein is related to their ability to fix complement
55. Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin/oligodendrocyte glycoprotein
56. Demyelination in primate autoimmune encephalomyelitis and acute multiple sclerosis lesions: A case for antigen specific antibody mediation
57. Multiple sclerosis: In situ evidence for antibody- and complement-mediated demyelination
58. Subacute leukoencephalitis caused by CNS infection with human herpesvirus-6 manifesting as acute multiple sclerosis
59. Plaque-associated expression of human herpesvirus 6 in multiple sclerosis
60. Chlamydia pneumoniae infection of the central nervous system in multiple sclerosis
61. Failure to detect Chlamydia pneumoniae in the central nervous system of patients with MS
62. Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis
63. Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination
64. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial
65. Interferon β-1b in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial
66. Magnetic resonance studies of intramuscular interferon β-1a for relapsing multiple sclerosis
67. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis
68. Effect of interferon β-1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: Results of a European multicenter, randomized, double-blind, placebo-controlled trial
69. Magnetization transfer changes in the normal appearing white matter precede the appearance of enhancing lesions in patients with multiple sclerosis
70. A histological, histochemical and biochemical study of the macroscopically normal white matter in multiple sclerosis
71. A serial study of new MS lesions and the white matter from which they arise
72. Pregnancy in Multiple Sclerosis Group Rate of pregnancy-related relapse in multiple sclerosis
73. Clinical viral infections and multiple sclerosis
74. A multicenter, randomized, double-blind, placebo-controlled trial of influenza immunization in multiple sclerosis
75. Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis
76. Interferon beta-1b in secondary progressive MS: Clinical and MRI results of a 3-year randomized controlled trial
77. The effect of anti-alpha4 integrin antibody on brain lesion activity in multiple sclerosis
78. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis
79. The Optic Neuritis Treatment Trial: Three-year follow-up results
80. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease
81. Interferon beta 1a (Rebif) in patients with acute neurological syndromes suggestive of multiple sclerosis: A multi-center, randomized, double-blind, placebo-controlled study
82. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis
83. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multi-center, randomized, double-blind, placebo-controlled trial
84. Copolymer I reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter, double-blind placebo-controlled trial
85. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability
86. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis
87. Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis
88. Population based cost utility study of interferon beta-1b in secondary progressive multiple sclerosis
89. Impairment, disability, and handicap in multiple sclerosis: A population-based study in Olmsted County, Minnesota
90. Evidence of interferon beta-1a dose response in relapsing-remitting MS
91. PRISMS 4-year results: Evidence of clinical dose effect of interferon beta-1a in relapsing MS
92. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis
93. Results of the 3-year, double-blind, placebo-controlled study of interferon beta-1a (Rebif) in secondary-progressive MS
94. 'Relapsing' versus 'nonrelapsing' SPMS: Different prognosis and response to interferon therapy in the SPECTRIMS study
95. Mitoxantrone in progressive multiple sclerosis: MRI results of the European phase III trial
96. Are clinical trials of therapeutic agents for MS long enough?
97. Treatment of multiple sclerosis: Recent trials and future perspectives
98. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2
99. TNF neutralization in MS: Results of a randomized, placebo-controlled multicenter study
100. Remyelination in multiple sclerosis: A challenge for therapy: The 1996 European Charcot Foundation Lecture
101. Myelination of the canine central nervous system by glial cell transplantation: A model for repair of human myelin disease
102. The Mayo Clinic-Canadian Cooperative Trial of sulfasalazine in active multiple sclerosis